{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.464.1003.196.12.1520","meta":{"versionId":"6","lastUpdated":"2021-02-02T10:23:16.000-05:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"NCQA PHEMUR Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2021-02-02"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1520","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.464.1003.196.12.1520"}],"version":"20200310","name":"Scopolamine","title":"Scopolamine","status":"active","experimental":false,"date":"2020-03-10T01:00:21-04:00","publisher":"NCQA PHEMUR","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: The purpose of this value set is to represent concepts for scopolamine medications.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent generic, human use, prescribable scopolamine and scopolamine in combination with other medications.),(Exclusion Criteria: Excludes concepts that represent non-prescribable or branded drugs and excludes concepts that represent components or ingredients.)","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1527"]}]},"expansion":{"identifier":"urn:uuid:0517b862-6c83-41fa-a070-356d3f1f6d72","timestamp":"2023-12-11T02:38:11-05:00","total":6,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1046787","display":"atropine sulfate 0.00388 MG/ML / hyoscyamine sulfate 0.0207 MG/ML / phenobarbital 3.24 MG/ML / scopolamine hydrobromide 0.0013 MG/ML Oral Solution"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1046815","display":"atropine sulfate 0.0194 MG / hyoscyamine sulfate 0.1037 MG / phenobarbital 16.2 MG / scopolamine hydrobromide 0.0065 MG Oral Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1046997","display":"atropine sulfate 0.0582 MG / hyoscyamine sulfate 0.311 MG / phenobarbital 48.6 MG / scopolamine hydrobromide 0.0195 MG Extended Release Oral Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1048124","display":"12 HR atropine sulfate 0.04 MG / chlorpheniramine maleate 8 MG / hyoscyamine sulfate 0.19 MG / pseudoephedrine hydrochloride 90 MG / scopolamine hydrobromide 0.01 MG Extended Release Oral Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"198207","display":"scopolamine 0.4 MG/ML Injectable Solution"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"226552","display":"72 HR scopolamine 0.0139 MG/HR Transdermal System"}]}}